Urocortin 3 Levels Are Impaired in Overweight Humans With and Without Type 2 Diabetes and Modulated by Exercise.
CRF
UCN3
diabetes
exercise
obesity
urocortin
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
05
2019
accepted:
21
10
2019
entrez:
30
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Urocortin3 (UCN3) regulates metabolic functions and is involved in cellular stress response. Although UCN3 is expressed in human adipose tissue, the association of UCN3 with obesity and diabetes remains unclear. This study investigated the effects of Type 2 diabetes (T2D) and increased body weight on the circulatory and subcutaneous adipose tissue (SAT) levels of UCN3 and assessed UCN3 modulation by a regular physical exercise. Normal-weight (
Identifiants
pubmed: 31781037
doi: 10.3389/fendo.2019.00762
pmc: PMC6851015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
762Informations de copyright
Copyright © 2019 Kavalakatt, Khadir, Madhu, Hammad, Devarajan, Abubaker, Al-Mulla, Tuomilehto and Tiss.
Références
Mol Cell Endocrinol. 2014 Jul 5;392(1-2):106-14
pubmed: 24859650
Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):837-43
pubmed: 18043308
Life Sci. 2007 Jan 2;80(4):356-63
pubmed: 17067638
JACC Basic Transl Sci. 2018 May 30;3(2):249-264
pubmed: 30062211
Can J Diabetes. 2015 Dec;39 Suppl 5:S129-33
pubmed: 26653253
Clin Chim Acta. 2017 Nov;474:76-87
pubmed: 28887029
Cell. 2010 Mar 19;140(6):900-17
pubmed: 20303879
Gen Comp Endocrinol. 2006 Mar;146(1):9-18
pubmed: 16413023
Endocrinology. 2004 Jan;145(1):24-35; discussion 21-3
pubmed: 12970163
PLoS One. 2006 Dec 20;1:e80
pubmed: 17183713
J Appl Physiol (1985). 2006 May;100(5):1584-9
pubmed: 16373444
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4206-11
pubmed: 17360501
Neuroendocrinology. 2005;82(5-6):282-93
pubmed: 16721034
Sci Rep. 2016 Aug 02;6:30958
pubmed: 27480913
J Mol Endocrinol. 2010 Aug;45(2):69-85
pubmed: 20501665
J Clin Invest. 2000 Aug;106(4):473-81
pubmed: 10953022
Front Neurosci. 2018 Nov 01;12:813
pubmed: 30443205
Gynecol Endocrinol. 2016;32(3):218-22
pubmed: 26488073
Clin Sci (Lond). 2004 Apr;106(4):383-8
pubmed: 14651473
Metabolism. 2016 Sep;65(9):1409-20
pubmed: 27506747
Peptides. 2014 Apr;54:58-66
pubmed: 24462512
Lipids Health Dis. 2018 Dec 22;17(1):291
pubmed: 30579336
J Cell Physiol. 2015 Nov;230(11):2821-8
pubmed: 25854185
Nat Med. 2001 May;7(5):605-11
pubmed: 11329063
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7570-5
pubmed: 11416224
Nat Med. 2015 Jul;21(7):769-76
pubmed: 26076035
Diabetologia. 2011 Sep;54(9):2392-403
pubmed: 21667214
Nat Commun. 2019 Jun 21;10(1):2757
pubmed: 31227697
Am J Physiol Endocrinol Metab. 2015 Jan 1;308(1):E71-83
pubmed: 25370852
Eur J Pharmacol. 2002 Apr 12;440(2-3):189-97
pubmed: 12007535
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16580-5
pubmed: 17050686
PLoS One. 2012;7(12):e52181
pubmed: 23251699
Int J Obes Relat Metab Disord. 2001 Jun;25(6):798-804
pubmed: 11439292
Front Endocrinol (Lausanne). 2013 Jan 07;3:180
pubmed: 23316185
Diabetes Metab. 2008 Feb;34 Suppl 2:S43-8
pubmed: 18640585
Front Neuroendocrinol. 2007 Apr;28(1):1-27
pubmed: 17083971
Trends Pharmacol Sci. 2003 Aug;24(8):421-7
pubmed: 12915052
Diabetes. 2000 Dec;49(12):2102-7
pubmed: 11118013
Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1800-5
pubmed: 15677523
J Endocrinol. 2014 Nov;223(2):143-54
pubmed: 25122003
Circ Res. 2019 Mar;124(5):799-815
pubmed: 30817262
Front Endocrinol (Lausanne). 2018 Feb 06;9:16
pubmed: 29467719
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8393-8
pubmed: 20404164
PLoS One. 2014 May 16;9(5):e97060
pubmed: 24835211
Placenta. 2010 Jun;31(6):475-81
pubmed: 20451246